Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
rare diseases
Pharma
ANI offers $560M to buy out rare disease pharma Egetis
ANI is poised to buyout Egetis Therapeutics and its lead asset Emcitate, the first and only approved treatment for MCT8 deficiency.
Donavyn Coffey
Nov 5, 2026 11:35am
AZ’s reported $10B offer for Rhythm fuels talks of a bidding war
Nov 5, 2026 9:36am
Inovio wins FDA nod for DNA-based immunotherapy in rare disease
Nov 2, 2026 10:53am
AZ lands 5th Ultomiris indication in kidney disease IgAN
Oct 22, 2026 11:15am
Roche's Enspryng muscles in on Tepezza's TED turf
Oct 16, 2026 9:26am
Ultragenyx cashes in a pair of FDA review vouchers for $413M
Oct 14, 2026 4:19pm
